文献速递免疫规划慢病防控与筛查

卢旺达人群中人乳头瘤病毒疫苗对HPV感染的效果:基于重复横断面宫颈细胞学调查的证据

Human papillomavirus vaccine effect against human papillomavirus infection in Rwanda: evidence from repeated cross-sectional cervical-cell-based surveys.
PubMed 文献 · Lancet Glob Health · 2023-05-16

研究在卢旺达基加利Nyarugenge区17-29岁性活跃女性中开展基线与重复横断面调查,比较HPV疫苗型别感染率。疫苗型HPV感染率从基线12%(173/1501)降至重复调查5%(89/1639),调整后总体疫苗效果47%(95%CI 31-60),间接疫苗效果32%(9-49)。

要点

  • 17-29岁女性HPV疫苗型感染率由12%(173/1501)降至5%(89/1639)。
  • 调整后总体疫苗效果47%(95%CI 31-60),间接疫苗效果32%(9-49)。
  • 17-23岁补种队列总体疫苗效果52%(95%CI 35-65),间接效果36%(8-55)。

核心结论

  • 卢旺达HPV疫苗项目显著降低了疫苗型HPV感染率,尤其在2011年补种项目期间在校的女性中。
  • 预计在12岁常规接种HPV疫苗的未来队列中,疫苗覆盖率和人群影响将增加。

研究设计与样本

  • 在卢旺达基加利Nyarugenge区健康中心,对17-29岁性活跃女性开展横断面调查,基线调查于2013年7月至2014年4月,重复调查于2019年3月至2020年12月。
  • 由医护人员采集宫颈细胞样本置于PreservCyt保存液中,采用通用引物(GP5+或GP6+)介导的PCR检测HPV。
  • 计算调整后总体、直接和间接(群体免疫)疫苗效果,分别基于所有女性和未接种女性中HPV检出百分比。

主要发现

  • 1501名参与者完成基线调查,1639名完成重复调查。
  • 17-29岁参与者HPV疫苗型感染率从基线12%(173/1501)降至重复调查5%(89/1639)。
  • 17-29岁参与者调整后总体疫苗效果47%(95%CI 31-60),调整后间接疫苗效果32%(9-49)。
  • 17-23岁补种合格参与者调整后总体疫苗效果52%(95%CI 35-65),调整后间接疫苗效果36%(8-55)。
  • 17-23岁参与者中,完成≥6年学校教育者总体疫苗效果68%(95%CI 51-79),<6年者16%(95%CI -34至47);HIV阴性者55%(95%CI 36-69),HIV阳性者24%(95%CI -62至64)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Rwanda was the first African country to implement national human papillomavirus (HPV) vaccination (against types HPV6, 11, 16, and 18). In 2011, a school-based catch-up programme was initiated to vaccinate girls aged younger than 15 years but it also reached older girls in schools. We aimed to estimate the population-level effect of HPV vaccination on HPV prevalence. METHODS: Cross-sectional surveys were done between July, 2013, and April, 2014 (baseline), and between March, 2019, and December, 2020 (repeat), in sexually active women aged 17-29 years at health centres in the Nyarugenge District of Kigali, Rwanda. HPV prevalence was assessed in cervical cell samples collected by a health-care worker in PreservCyt solution (Cytyc, Boxbourough, MA, USA) and tested using a general primer (GP5+ or GP6+)-mediated PCR. Adjusted overall, total, and indirect (herd immunity) vaccine effectiveness was computed as the percentage of HPV detection among all women and among unvaccinated women. FINDINGS: 1501 participants completed the baseline survey and 1639 completed the repeat survey. HPV vaccine-type prevalence in participants aged 17-29 years decreased from 12% (173 of 1501) in the baseline survey to 5% (89 of 1639) in the repeat survey, with an adjusted overall vaccine effectiveness of 47% (95% CI 31 to 60) and an adjusted indirect vaccine effectiveness of 32% (9 to 49). Among participants aged 17-23 years, who were eligible for catch-up vaccination, the adjusted overall vaccine effectiveness was 52% (35 to 65) and the adjusted indirect vaccine effectiveness was 36% (8 to 55), with important heterogeneity according to education (overall vaccine effectiveness was 68% [51 to 79] in participants with ≥6 years of school completed and 16% [-34 to 47] in those with <6 years) and HIV status (overall vaccine effectiveness was 55% [36 to 69] for HIV-negative participants and 24% [-62 to 64] for HIV-positive participants). INTERPRETATION: In Rwanda, the prevalence of vaccine-targeted HPV types has been significantly decreased by the HPV vaccine programme, most notably in women who were attending school during the catch-up programme in 2011. HPV vaccine coverage and population-level impact is expected to increase in future cohorts who are eligible for routine HPV vaccination at age 12 years. FUNDING: Bill & Melinda Gates Foundation.

来源:Lancet Glob Health,查看原文。版权归原作者所有。

引用

  1. Sayinzoga F, Tenet V, Heideman DAM, et al. Human papillomavirus vaccine effect against human papillomavirus infection in Rwanda: evidence from repeated cross-sectional cervical-cell-based surveys. Lancet Glob Health. 2023. PMID: 37207683. doi:10.1016/S2214-109X(23)00193-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。